Washington biologics regulations.

Who may administer PRP, exosomes and stem cells in Washington, and which agencies to check.

A physician at a desk reading regulatory documents

Who may administer biologics in Washington?

In Washington, only licensed healthcare professionals such as physicians (MD/DO) and nurse practitioners are authorized to administer stem cell and biologic treatments under physician supervision.

Official sources

Washington compliance guide.

FDA Compliance

The U.S. Food and Drug Administration (FDA) regulates human cells, tissues, and cellular and tissue-based products (HCT/Ps), including biologics. Clinics are required to follow the FDA’s Investigational New Drug (IND) application process or 21 CFR Part 1271 for therapies that do not meet the standards of minimal manipulation and homologous use. Compliance with these federal standards is crucial for all providers.

Washington State Regulations

Washington also has specific regulations that complement federal guidelines on biologics. For detailed requirements, visit the Washington State Department of Health. Clinics should consult state resources to ensure full compliance with Washington’s licensing and operational standards.

Provider Qualifications

In Washington, only licensed healthcare professionals such as physicians (MD/DO) and nurse practitioners are authorized to administer stem cell and biologic treatments under physician supervision. Requirements include proper licensure and, in some cases, specialized training or certifications as mandated by the Washington Medical Commission.

Patient Informed Consent

Washington requires providers to obtain comprehensive informed consent from patients. Consent should cover:

  • A detailed explanation of the experimental nature of certain biologic treatments, as some are not FDA-approved.
  • A clear outline of the potential benefits, risks, and uncertainties associated with the treatment.
  • An option for patients to consider alternative treatments and an emphasis on the voluntary nature of participation in these therapies.

Additional Compliance Areas

Pre-Treatment and Post-Treatment Protocols

Establishing pre-treatment screenings and post-treatment follow-up protocols is essential in Washington. These protocols help minimize risks and ensure high standards of patient care.

Standard Operating Procedures (SOPs)

Implementing SOPs for each stage of patient care, from initial evaluation to follow-up, promotes uniformity in treatment practices and quality standards.

Medical Liability Insurance

Clinics offering biologics should maintain adequate medical liability insurance, customized to cover biologic treatments and therapies. Consult with a qualified insurance provider to determine appropriate coverage options for Washington practitioners.

Marketing and Advertising Compliance

Marketing materials should adhere to Washington’s regulations for medical advertising. Avoid any claims of guaranteed outcomes, and disclose the investigational status of certain therapies to prevent misleading representations.

This guide is a general summary to help clinics understand compliance requirements for biologics in Washington. It is not legal advice. Regulations change; consult legal counsel and the agencies above before acting on it.

Washington: common questions.

Who can administer stem cells, PRP and exosomes in Washington?
In Washington, only licensed healthcare professionals such as physicians (MD/DO) and nurse practitioners are authorized to administer stem cell and biologic treatments under physician supervision. This is a general summary, not legal advice. Confirm with the state board.
Are stem cell and exosome therapies FDA-approved in Washington?
FDA rules are federal, so they apply in Washington as everywhere else. Exosome and stem cell therapies are not FDA-approved for therapeutic use, and PRP applications are considered off-label.
Do I need an IRB-approved study to offer biologics in Washington?
Investigational treatment belongs inside a reviewed study with proper informed consent. IRB review is not FDA authorisation: culture-expanded and other more-than-minimally-manipulated cell products generally need an IND before use in people.
How do I start offering biologics in Washington?
Start with the live webinar, then a discovery call and live training. After that we verify your Washington licence, protocol, product sourcing, consent process and advertising before you are listed for patient inquiries.

Practising in Washington? Start with the webinar.

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.